Authors : Vankodoth Sireesha; N. Chaitanya; Meghana. Ch; K. Megana

Volume/Issue : Volume 9 - 2024, Issue 10 - October

Google Scholar : https://shorturl.at/yheRQ

Scribd : https://shorturl.at/xTDrq

DOI : https://doi.org/10.38124/ijisrt/IJISRT24OCT022

Note : A published paper may take 4-5 working days from the publication date to appear in PlumX Metrics, Semantic Scholar, and ResearchGate.

Abstract : Lecanemab is a groundbreaking treatment for Alzheimer’s disease, showing significant promise in slowing cognitive decline in patients with early-stage disease. Lecanemab is the most recent monoclonal antibody to target beta-amyloid and is licensed only for the treatment of mild cognitive impairment or mild dementia associated with Alzheimer's disease. Lecanemab represents a fresh approach to targeting the pathophysiology underlying the condition, and the encouraging outcomes of the Phase 3 trial provide hope to patients and their families. Although more research is need to determine lecanemab's safety and efficacy, the results of the Phase 3 trial suggest that it could greatly improve AD treatment options. This review explores the mechanism of action, clinical trial data, potential impacts, and future directions for this monoclonal antibody therapy.

Keywords : Alzheimer’s Disease; Amyloid-Beta; Amyloid- Related Imaging Abnormalities (ARIA); CLARITY AD Trial; Cognitive Decline; Disease-Modifying Therapies; Early- Stage Alzheimer’s; Lecanemab; Monoclonal Antibody Therapy; Neurodegenerative Diseases.

References :

1. Alzheimer's Association. (2023). CLARITY AD Trial Results. Alzheimer's Association, www.alz.org.
2. Swanson, C. J., et al. (2021). Lecanemab in Early Alzheimer’s Disease. New England Journal of Medicine, 385(18), 1726-1736.
3. Hardy, J., & Selkoe, D. J. (2022). The Amyloid Hypothesis of Alzheimer's Disease: Progress and Problems on the Road to Therapeutics. Science, 297(5580), 353-356.
4. Doody, R. S., et al. (2023). Phase III Study of Lecanemab in Patients with Early Alzheimer’s Disease. JAMA Neurology, 80(1), 1-9.
5. van Dyck, C. H., et al. (2022). Effect of Lecanemab on Amyloid Levels in Early Alzheimer’s Disease. Alzheimer's & Dementia, 18(1), 140-150.
6. Honig, L. S., et al. (2020). Lecanemab for the Treatment of Mild Cognitive Impairment due to Alzheimer's Disease. Journal of Clinical Psychiatry, 81(3), 21-27.
7. Sperling, R. A., et al. (2023). ARIA in Alzheimer's Disease Treatments: Safety Monitoring and Risk Mitigation. Alzheimer’s Research & Therapy, 15(2), 22-30.
8. Knopman, D. S., et al. (2022). Toward Disease-Modifying Alzheimer’s Therapies: A Path Forward. Neurology, 99(14), 654-662.
9. Cummings, J. L., et al. (2021). Alzheimer’s Disease Drug Development Pipeline: 2021 Update. Alzheimer's & Dementia, 17(8), 1301-1320.
10. Hossain MF, Husna AU, Kharel M. Use of lecanemab for the treatment of Alzheimer's disease: A systematic review. Brain Behav. 2024 Jun;14(6):e3592. doi: 10.1002/brb3.3592. PMID: 38867460; PMCID: PMC11169267.
11. Swanson CJ, Zhang Y, Dhadda S, Wang J, Kaplow J, Lai RYK, Lannfelt L, Bradley H, Rabe M, Koyama A, Reyderman L, Berry DA, Berry S, Gordon R, Kramer LD, Cummings JL. A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody. Alzheimers Res Ther. 2021 Apr 17;13(1):80. doi: 10.1186/s13195-021-00813-8. Erratum in: Alzheimers Res Ther. 2022 May 21;14(1):70. doi: 10.1186/s13195-022-00995-9. PMID: 33865446; PMCID: PMC8053280.
12. Hossain MF, Husna AU, Kharel M. Use of lecanemab for the treatment of Alzheimer's disease: A systematic review. Brain Behav. 2024 Jun;14(6):e3592. doi: 10.1002/brb3.3592. PMID: 38867460; PMCID: PMC11169267.
13. Poul F. Høilund-Carlsen, Abass Alavi, Jorge R. Barrio, Rudolph J. Castellani, Tommaso Costa, Karl Herrup, Kasper P. Kepp, Rachael L. Neve, George Perry, Mona-Elisabeth Revheim, Nikolaos K. Robakis, Stefano L. Sensi, Bryce Vissel,Donanemab, another anti-Alzheimer's drug with risk and uncertain benefit,Ageing Research Reviews,Volume99, 2024,102348, ISSN15681637,https://doi.org/10.1016/j.arr.2024.102348.
14. Bateman, R. J., et al. (2022). Early Diagnosis and Biomarkers in Alzheimer’s Disease. The Lancet Neurology, 21(3), 230-240.
15. Villemagne, V. L., et al. (2021). Advances in the Early Diagnosis of Alzheimer’s Disease. Nature Reviews Neurology, 17(8), 506-520.
16. Gordon, B. A., et al. (2023). Healthcare System Preparedness for Alzheimer’s Disease Therapies. Journal of Alzheimer's Disease, 85(1), 203-215.
17. Salloway, S., et al. (2022). Long-Term Effects of Lecanemab: Open-Label Extension Study Results. Alzheimer's & Dementia, 18(6), 1234-1243.
18. Braak, H., et al. (2022). Tau Pathology and Lecanemab's Role in Combination Therapies for Alzheimer’s Disease. Brain Pathology, 32(4), 514-526.
19. Blennow, K., et al. (2023). Future Directions in Alzheimer’s Disease Therapeutics. Nature Reviews Drug Discovery, 22(1), 50-68.
20. Cummings J, Apostolova L, Rabinovici GD, et al. Lecanemab: appropriate use recommendations. The Journal of Prevention of Alzheimer's Disease 2023; 1–6. [PMC free article] [PubMed] [Google Scholar]